Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases
Moritz J. Schmidt(Boehringer Ingelheim (Germany)), Wayne M. Coco(Bayer (Germany)), Akiko Noma(Broad Institute), Brian J. Cafferty(Akebia Therapeutics (United States)), Karolina Kosakowska(Akebia Therapeutics (United States)), Shailendra Sane(Akebia Therapeutics (United States)), Mariacarmela Allocca(Center for Environmental Health), Stefanie Gehrig-Giannini(Bayer (Germany)), Cindy Park‐Windhol(Rhode Island Hospital), Sarah J. Spencer, Christien Bednarski(Bayer (Germany)), C.W. Reiss(Akebia Therapeutics (United States)), Albena Kantardzhieva(Massachusetts Eye and Ear Infirmary), Jan Tebbe(Bayer (Germany)), Ashish Gupta(Shiv Nadar University), André Cohnen(Bayer (Germany)), Andrew M. Scharenberg(CTI BioPharma (Italy)), Abraham Scaria(Akebia Therapeutics (United States)), Ryo Takeuchi(Fred Hutch Cancer Center), Kerstin Dehne(Bayer (Germany)), Scott Munzer(Akebia Therapeutics (United States)), Christina Galonska(Max Planck Institute for Molecular Genetics), Michael Lukason, Kui Wang(Second Affiliated Hospital of Xi'an Jiaotong University), Florian Richter(Technische Hochschule Mannheim), Michael Gamalinda(Bayer (Germany)), Christopher J. Cheng(Akebia Therapeutics (United States)), Christian Pitzler(Bayer (Germany))
Cited by 57
Related Papers
ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology
|Nature|2001|897
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840